Edited by Jeffrey E. PessinMice harboring a particular allele of the human brain-derived neurotropic factor (BDNF M/M mice) develop extreme obesity and insulin resistance when fed a high-fat diet. The underlying mechanisms of this genetic risk factor for obesity are unclear. In the current issue of JBC, Yang et al. report that pharmacological inhibition of integral membrane protein CD36 significantly reduces body weight gain and improves glucose tolerance in BDNF M/M mice. Targeting CD36 may therefore be a promising strategy to improve metabolic dysfunctions and normalize risk factors in obese individuals.Obesity is a major health risk that can contribute to lifethreatening metabolic complications including dyslipidemia and type 2 diabetes (1). The pathogenesis of obesity involves complex interactions between environmental and genetic factors, leading to dysregulated energy balance. Genetic variants, including single-nucleotide polymorphisms (SNPs), 2 account for 40 -70% of the heritability of body mass index (BMI) (2). One such SNP that is associated with body weight regulation is a mutation in the gene for brain-derived neurotrophic factor (BDNF).BDNF plays a critical role in nervous system development and function, including the regulation of energy intake and expenditure (3). One common polymorphism in the BDNF gene is a substitution of a valine with a methionine at codon 66 (Val66Met SNP) (4). The Val66Met allele has been associated with several disorders, including early seizures, obsessive-compulsive disorder, eating disorders, and obesity in humans (5).Yang et al. (6) used a unique mouse model containing the human BDNF Val66Met variant and found that, consistent with observations in humans, BDNF M/M mice fed a normal diet had significantly increased body weight relative to BDNF V/V controls by 6 weeks of age. When subsequently fed a high-fat diet for 8 weeks, the BDNF M/M mice became extremely obese with elevated fasting glucose levels and impaired glucose tolerance, implying the development of insulin resistance. The authors specifically investigated the connection between these phenotypes and the expression of integral membrane protein CD36, a multifunctional receptor with documented links to obesity-associated metabolic disorders. They found that, compared with controls, BDNF M/M mice had significantly increased levels of CD36 mRNA and protein, including the soluble form (sCD36), which is a marker of insulin resistance in diabetes (7). Thus, changes in BDNF were correlated with changes in CD36 and associated metabolic phenotypes.CD36, a class B scavenger receptor, functions as a fatty acid transporter to promote fatty acid uptake. CD36 is thought to mediate cross-talk between adipocytes and macrophages in obese mice by facilitating cytokine secretion from macrophages (8). To identify the role of CD36 in the development of obesity in BDNF M/M mice, Yang et al. (6) used salvianolic acid B (SAB), a specific CD36 antagonist, in experiments both in vitro and in vivo (9). Although chronic administration of ...